Lyndra lays off 23% of workers, to outsource manufacturing as it approaches pivotal readout next month
Lyndra Therapeutics is letting go about 23% of its workforce as the Boston-area biotech seeks to trim operational costs ahead of a pivotal trial readout …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
